EP1458396A1 - 4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3 - Google Patents

4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3

Info

Publication number
EP1458396A1
EP1458396A1 EP02805750A EP02805750A EP1458396A1 EP 1458396 A1 EP1458396 A1 EP 1458396A1 EP 02805750 A EP02805750 A EP 02805750A EP 02805750 A EP02805750 A EP 02805750A EP 1458396 A1 EP1458396 A1 EP 1458396A1
Authority
EP
European Patent Office
Prior art keywords
hcl
formula
compounds
solvates
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02805750A
Other languages
German (de)
English (en)
Inventor
Rolf Gericke
Norbert Beier
Claudia Wilm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1458396A1 publication Critical patent/EP1458396A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the invention relates to compounds of the formula I.
  • Ar is phenyl or naphthyl which is substituted by X and is additionally substituted by R 3 and R 4 ,
  • R 1 . 2 , R 3 , R 4 each independently of one another H, A, OA, Hai, CF 3 , OH, N0 2 , NH 2 , NHA, NA 2l NH-CO-A, NH-CO-Ph, SA, SO-A , S0 2 -A, S0 2 - Ph, CN, OCF 3 , CO-A, C0 2 H, C0 2 A, CO-NH 2) CO-NHA, CO-NA 2l SO 2 NH 2 , S0 2 NHA, SO2NA2 or unsubstituted or mono- or polysubstituted by A, OA, shark or CF 3 ,
  • R 5 denotes H, A, OH, N0 2 , unsubstituted or mono- or polysubstituted by A, OA, shark, CF 3 , an amino-protecting group or
  • R 6 , R 7 each independently of one another are H, A, unsubstituted or mono- or polysubstituted by A, OA, shark or CF 3, phenyl, benzyl, an amino protecting group or- (CH 2 ) n NR 10 R 11 ,
  • R 8 , R 9 each independently of one another H or A,
  • R 10 , R 11 each independently of one another are H, A, unsubstituted or mono- or polysubstituted by A, OA, shark or CF 3
  • the invention also relates to the use of the compounds of the formula I and their salts and solvates as NHE-3 inhibitors.
  • the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments.
  • the compounds of the formula I and their salts inhibit the sodium / proton exchanger subtype 3 with good tolerance and at the same time have improved bioavailability due to their increased water solubility.
  • the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine.
  • the Na + / H + exchanger is a family with at least 6 different isoforms (NHE-1 to NHE-6), all of which are already cloned. While the NHE-1 subtype is ubiquitously distributed throughout the body in all tissues, the other NHE subtypes are selectively expressed in specific organs such as in the kidney or in the lumen wall and contraluminal wall of the small intestine. This distribution reflects the specific functions that the different isoforms serve, namely the regulation of the intracellular pH and cell volume by the subtype NHE-1 on the one hand and the Na + uptake and reuptake in the intestine and kidney by the other Isoforms NHE-2 or NHE-3. The NHE-4 isoform was found mainly in the stomach. The expression of NHE-5 is limited to brain and neuronal tissue. NHE-6 represents the isoform that forms the sodium proton exchanger in the mitochondria.
  • the NHE-3 isoform is expressed in particular in the apical membrane of the proximal kidney tubules; an NHE-3 inhibitor therefore exerts a protective effect on the kidneys.
  • the therapeutic use of a selective inhibitor for NHE-3 isoforms is versatile. NHE-3 inhibitors inhibit or reduce tissue damage and cell necrosis following pathophysiological hypoxic and ischemic events that lead to activation of NHE activity, such as during renal ischemia or during kidney transplant removal, transport, and reperfusion during kidney transplantation ,
  • the compounds of the formula I have a cytoprotective effect by preventing the excessive absorption of sodium and water in the cells of organs which are under-supplied with oxygen.
  • the compounds of formula I lower blood pressure and are suitable as active pharmaceutical ingredients for the treatment of hypertension. They are also suitable as diuretics.
  • the compounds of formula I alone or in combination with NHE inhibitors of other subtype specificity, have anti-ischemic effects and can be used in thromboses, atherosclerosis, vascular spasms, for protecting organs, e.g. Kidney and liver, before and during operations, as well as with chronic or acute kidney failure. They can also be used to treat stroke, cerebral edema, ischemia of the nervous system, various forms of shock, e.g. of allergic, cardiological, hypovolaean or bacterial shock, as well as to improve respiratory drive in the following conditions, for example: central sleep apnea, sudden child death, postoperative hypoxia and other breathing disorders.
  • Combination with a carbonic anhydrase inhibitor can further improve breathing.
  • the compounds of the formula I have an inhibitory effect on the proliferation of cells, for example fibroblast cell proliferation and the proliferation of smooth vascular muscle cells and can therefore be used for the treatment of diseases in which cell proliferation is a primary or secondary cause.
  • the compounds of the formula I can be used against late diabetic complications, cancer, fibrotic diseases, endothelial dysfunction, organ hypertrophies and organ hyperplasias, particularly in the case of prostate hyperplasia or prostate hypertrophy. They are also suitable as diagnostics for the determination and differentiation of certain forms of hypertension, atherosclerosis, diabetes and proliferative diseases.
  • the compounds of the formula I also have an advantageous effect on the level of the serum lipoproteins, they can be used to treat an elevated level
  • Blood lipid levels can be used alone or in combination with other medicines.
  • the invention relates to the use of compounds of the formula I according to claim 1 and their physiologically acceptable salts and / or solvates for the manufacture of a medicament for the treatment of thromboses, ischemic conditions of the heart, peripheral and central nervous system and stroke, ischemic conditions of peripheral organs and limbs and for the treatment of shock conditions.
  • the invention further relates to the use of compounds of the formula I according to claim 1 and their physiologically acceptable salts and / or solvates for the production of a medicament for use in surgical operations and organ transplants and for the preservation and storage of transplants for surgical measures.
  • the invention also relates to the use of compounds of the formula I according to claim 1 and their physiologically acceptable salts and / or solvates for the manufacture of a medicament for the treatment of diseases in which cell proliferation is a primary or secondary cause, for the treatment or prophylaxis of disorders of fat metabolism or disturbed respiratory drive.
  • the invention further relates to the use of compounds of the formula I according to claim 1 and their physiologically acceptable salts and / or solvates for the manufacture of a medicament for the treatment of ischemic kidney, ischemic bowel disease or for the prophylaxis of acute or chronic kidney disease.
  • Methods for identifying substances which inhibit the sodium / proton exchanger subtype 3 are described, for example, in US Pat. No. 5,871,919.
  • the compounds of the formula I are also suitable for the treatment of bacterial and parasitic diseases.
  • Hydrates and solvates are e.g. the hemi-, mono- or dihydrates, among solvates e.g. Alcohol addition compounds such as with methanol or ethanol.
  • A means alkyl, is linear or branched, and has 1, 2, 3, 4, 5 or 6 carbon atoms.
  • A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2 , 2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3 , 3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl.
  • OA preferably means methoxy, ethoxy, propoxy, isopropoxy or butoxy.
  • Shark preferably means F, CI or Br, but also I, in particular F, CI or Br.
  • Ph denotes an unsubstituted phenyl radical, unless stated otherwise.
  • Ar is preferably phenyl which is monosubstituted by X and, for example, A, fluorine, chlorine, bromine, iodine, methoxy, ethoxy, propoxy, butoxy or CF 3 .
  • Ar particularly preferably denotes one of the following radicals: wherein R _3, R and X have the meaning given above.
  • X is preferably NR) 6r R-, 7, a 5 to 7-membered ring with 2 N atoms or the following radical:
  • R »12 is H, A, Ph, benzyl or an amino protecting group such as BOG or GBO and in particular H, A or phenyl.
  • R 5 preferably denotes H, A, OH N0 2 or an amino protecting group, in particular H, A, OH or NO 2 .
  • R 6 and R 7 are preferably simultaneously H, independently of one another H, A, benzyl or - (CH 2 ) n NA 2 .
  • R 8 and R 9 are preferably H or methyl, in particular H.
  • R 10 and R 11 are preferably H, A, benzyl or phenyl, in particular H, methyl or benzyl. *
  • n is preferably 2.
  • amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other locations in the molecule. Unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups are particularly typical of such groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their type and size is otherwise not critical; however, preference is given to those having 1-20, in particular 1-8, carbon atoms.
  • acyl group encompasses acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups.
  • amino protecting groups are alkanoyl such as acetyl, propio- nyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as POA; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; Alkenyloxycarbonyl such as allyloxycarbonyl (aloe), aralkyoxyoxyyl such as CBZ ("carbobenzoxy", synonymous with Z), 4-
  • Methoxybenzyloxycarbonyl (MOZ), 4-nitro-benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl (FMOC2- (phenylsulfonyl) ethoxycarbonyl; trimethylsilylethoxycarbonyl (Teoc) or arylsulfonyl such as 4-methoxy-2,3,6-trimethylphenylsulfonyl (Mtr) means preferably formyl, acetyl, propionyl, butyryl, phenylacetyl, benzoyl, toluyl, POA, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl, CBZ ("carbobenzoxy”), 4-methoxybenzyloxycarbonyl, FMOC, Mtr or benzyl.
  • Mtr 4-methoxy-2,3,6-trimethylphen
  • the invention relates in particular to the compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above and the use thereof.
  • R, 1, R, Ar and Y have the meanings given above.
  • R 1 in formulas IA, IB and IC means H, while R 2 means shark and in particular CI.
  • Y preferably has one of the following meanings:
  • Y particularly preferably has one of the following meanings:
  • Chlorides and p-toluenesulfonates of the compounds of the formulas 11 are very particularly preferred.
  • the compounds of the formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (for example in the standard works such as Houben-Weyl, methods of organic chemistry, Georg-Thieme-Verlag, Stuttgart) are described, namely under reaction conditions which are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail.
  • the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
  • the compounds of formula I are preferably prepared by using compounds of formula II
  • R 1 , R 2 and Ar have the meanings given above, with 1-cyanguanidine or a corresponding N-alkylated or N-arylated 1-cyanguanidine of the formula NC-Y, wherein Y has the meaning given above and z is 0.
  • the reaction can be carried out in a preferably inert solvent.
  • Suitable solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether,
  • Tetrahydrofuran (THF) or dioxane Tetrahydrofuran (THF) or dioxane
  • Glycol ethers such as ethylene glycol mono- methyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of the solvents mentioned.
  • DMF water or an alcohol
  • the reaction is very particularly preferred without a solvent, i.e. in the melt, carried out at temperatures between 100 and 200 ° C.
  • an acidic catalyst such as AICI 3 , TiCU, p-toluenesulfonic acid, BF 3 , acetic acid, sulfuric acid, oxalic acid, POCI 3 or phosphorus pentoxide is advantageous.
  • a preferred variant is that at least one of the reactants is already in the form of a salt, e.g. is used as the hydrochloride.
  • Y has the meaning given above, z being 0, alkyl preferably the meaning of A above and aryl the meaning of Ar given above, with a compound of the formula II.
  • HY particularly preferably means guanidine or a compound of the following formula:
  • R 5 has the meaning given above.
  • a strong base such as alkali alcoholate or strongly basic amines.
  • a strong base such as alkali alcoholate or strongly basic amines.
  • alkali alcoholate or strongly basic amines sodium or potassium methoxide or ethanolate, potassium tert-
  • Compounds of the formula HY are preferably DMSO, NMP or
  • the compounds of formula IV can be obtained by production methods known per se.
  • the compounds of the formula IV are particularly preferred by reacting the compounds of the formula V
  • radicals R 1 , R 2 , R 3 , R 4 and other functional groups only after the reaction of the compounds of the formula II with the compounds of the formula NC-Y or the compounds of the formula III, for example by removing a protective group, ether cleavage or hydrogenation of nitro groups to amino groups. Accordingly, it may also be sensible to generate the radicals R 1 , R 2 , R 3 , R 4 and other functional groups only after the reaction of the compounds of the formula IV with the compounds of the formula HY by the measures mentioned above.
  • the compounds of formula I, wherein X is NR 6 R 7 or a saturated 5-7 membered ring with two N atoms, are preferably from the halogen compounds of formula VI
  • Any free amino groups that may be present must be protected from the reaction, for example by amino protecting groups.
  • a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
  • acids that contain physiologically acceptable salts are suitable for this implementation. ze deliver.
  • So inorganic acids can be used, for example sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polycarbonate, sulfonic or Sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, ethanoic acid sulfonic acid, methonic acid sulfonic acid, methonic acid sulfonic acid, methonic acid sulfonic acid, 2-hydroxyethanesulfonic acid, benzene
  • the invention furthermore relates to the use of the compounds of the formula I as NHE-3 inhibitors and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular in a non-chemical way. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
  • the invention further relates to pharmaceutical preparations containing at least one NHE-3 inhibitor of the formula I and / or one of its physiologically acceptable salts and solvates.
  • Suitable carriers are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin , Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
  • the new compounds can also be lyophilized and the lyophilizates obtained e.g. can be used for the production of injectables.
  • the specified preparations can be sterilized and / or contain auxiliary substances such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active substances, eg one or more vitamins.
  • Suitable pharmaceutical preparations for administration in the form of aerosols or sprays are e.g. Solutions, suspensions or emulsions of the active ingredient of formula I in a pharmaceutically acceptable solvent.
  • the compounds of formula I and their physiologically acceptable salts and solvates can be used for the treatment and / or prophylaxis of the above. described diseases or disease states can be used.
  • the substances according to the invention are generally preferably administered in doses between about 0.1 and 100 mg, in particular between 1 and 10 mg, per dosage unit.
  • the daily dose is preferably between about 0.001 and 10 mg / kg body weight.
  • the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of excretion and on the combination of drugs and severity of the respective disease to which the therapy applies. Oral application is preferred.
  • NHE-3 inhibitors were obtained as acid addition salts or free bases analogously to the processes given above using the corresponding precursors:
  • pTsOH means p-toluenesulfonic acid.
  • the compounds of formula I are characterized in terms of their selectivity towards the isoforms NHE-1 to NHE-3.
  • the three isofor Men are stably expressed in mouse fibroblast cell lines.
  • the inhibitory effect of the compounds is assessed by determining the ElPA-sensitive 22 Na + uptake into the cells after intracellular acidosis.
  • the LAP1 cell lines expressing the isoforms NHE-1, -2 and -3 were obtained from Prof. J. Pouyssegur (Nice, France). The transfections are carried out according to the method of Franchi et al. (1986). The cells are cultured in Dulbecco's modified Eagle medium (DMEM) with 10% inactivated fetal calf serum (FKS). To select the NHE-expressing cells, the so-called "acid killing method" by Sardet et al. (1989) used. The cells are first incubated for 30 minutes in an NHCI-containing bicarbonate and sodium-free buffer.
  • DMEM Dulbecco's modified Eagle medium
  • FKS inactivated fetal calf serum
  • the extracellular NH 4 CI is then removed by washing with a buffer free of bicarbonate, NH 4 CI and sodium.
  • the cells are then incubated in a bicarbonate-free, NaCl-containing buffer. Only those cells that functionally express NHE can survive in the intracellular acidification to which they are exposed.
  • mice fibroblast cell lines which express the isoforms NHE-1, NHE-2 and NHE-3
  • compounds according to the method described by Counillon et al. (1993) and Scholz et al. (1995) tested the procedure for selectivity compared to the isoforms.
  • the cells are acidified intracellularly using the NH CI prepulse method and then by incubation in a bicarbonate-free 22 Na + -containing buffer. Due to the intracellular acidification, NHE is activated and sodium is absorbed into the cells.
  • the effect of the test compound is expressed as an inhibition of the 22 Na + uptake sensitive to EIPA (ethyl isopropylamiloride).
  • the cells expressing NHE-1, NHE-2 and NHE-3 are seeded in a density of 5-7.5 x 10 4 cells / well in microtiter plates with 24 wells and grown to confluence for 24 to 48 hours.
  • the medium is suctioned off and the cells are incubated for 60 minutes at 37 ° C. in the NHCI buffer (50 mM NH 4 CI, 70 mM choline chloride, 15 mM MOPS, pH 7.0).
  • the buffer is then removed and the cells are rapidly overlaid twice with the choline chloride washing buffer (120 mM choline chloride, 15 mM PIPES / Tris, 0.1 mM ouabain, 1 mM MgCl 2 , 2 mM CaCl 2 , pH 7.4) aspirated.
  • the choline chloride washing buffer 120 mM choline chloride, 15 mM PIPES / Tris, 0.1 mM ouabain, 1 mM MgCl 2 , 2 mM CaCl 2 , pH 7.4
  • the cells with the choline chloride loading buffer (120 mM choline chloride, 15 mM PIPES / Tris, 0.1 mM PIPES / Tris, 0.1 mM Quabain, 1mM MgCl 2 , 2mM CaCl 2 , pH 7.4, 2 Na + (0.925 kBg / 100 ml loading buffer)) and incubated therein for 6 minutes. After the incubation period has expired, the incubation buffer is aspirated. To remove extracellular radioactivity, the cells are quickly washed four times with ice-cold phosphate-buffered saline (PBS).
  • PBS ice-cold phosphate-buffered saline
  • the cells are then solubilized by adding 0.3 ml of 0.1 N NaOH per well.
  • the solutions containing the cell fragments are transferred to scintillation tubes.
  • Each well is washed twice more with 0.3 ml of 0.1 N NaOH and the washing solutions are also added to the corresponding scintillation tubes.
  • the tubes containing the cell lysate are mixed with scintillation cocktail and the radioactivity absorbed into the cells is determined by determining the ⁇ radiation.
  • Example A Injection glasses A solution of 100 g of an NHE-3 inhibitor of the formula I and 5 g of sodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sterile closed. Each injection glass contains 5 mg of active ingredient.
  • a mixture of 20 g of an NHE-3 inhibitor of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
  • Example D ointment
  • a mixture of 1 kg of an NHE-3 inhibitor of the formula 1, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet 10 mg contains active ingredient.
  • Example F coated tablets Analogously to Example E, tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
  • Example G capsules
  • a solution of 1 kg of NHE-3 inhibitor of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), dans laquelle Ar est phényl ou naphtyl substitué par X, également substitué par R3 et R4 ; Y est (A), (B) ou (C) ; X est H, NR6R7 ou un cycle saturé à 5-7 éléments comportant deux atomes de N ; et, R1, R2, R3, R4 sont indépendamment l'un de l'autre H, A, OA, Hal, CF3, OH, NO2, NH2, NHA, NA2, NH-CO-A, NH-CO-Ph, SA, SO-A, SO2-A, SO2-Ph, CN, OCF3, CO-A, CO2H, CO2A, CO-NH2, CO-NHA, CO-NA2, SO2NH2, SO2NHA, SO2NA2 ou phényl non susbstitué ou substitué une ou plusieurs fois par A, OA, Hal ou CF3. L'invention concerne également les sels et solvates desdits composés ainsi que leur utilisation en tant qu'inhibiteurs de NHE-3.
EP02805750A 2001-12-24 2002-11-29 4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3 Withdrawn EP1458396A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10163992A DE10163992A1 (de) 2001-12-24 2001-12-24 4-Aryl-chinazoline
DE10163992 2001-12-24
PCT/EP2002/013530 WO2003055490A1 (fr) 2001-12-24 2002-11-29 4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3

Publications (1)

Publication Number Publication Date
EP1458396A1 true EP1458396A1 (fr) 2004-09-22

Family

ID=7710890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02805750A Withdrawn EP1458396A1 (fr) 2001-12-24 2002-11-29 4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3

Country Status (11)

Country Link
US (1) US20050020612A1 (fr)
EP (1) EP1458396A1 (fr)
KR (1) KR20040066856A (fr)
AR (1) AR037973A1 (fr)
AU (1) AU2002356762A1 (fr)
BR (1) BR0215294A (fr)
CA (1) CA2471524A1 (fr)
DE (1) DE10163992A1 (fr)
MX (1) MXPA04006193A (fr)
PL (1) PL369855A1 (fr)
WO (1) WO2003055490A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043667A1 (de) * 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
US7629967B2 (en) 2003-02-14 2009-12-08 Next Holdings Limited Touch screen signal processing
US8508508B2 (en) 2003-02-14 2013-08-13 Next Holdings Limited Touch screen signal processing with single-point calibration
US8456447B2 (en) 2003-02-14 2013-06-04 Next Holdings Limited Touch screen signal processing
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US7538759B2 (en) 2004-05-07 2009-05-26 Next Holdings Limited Touch panel display system with illumination and detection provided from a single edge
GB0526515D0 (en) * 2005-12-28 2006-02-08 Merck Sharp & Dohme Modulation of signalling pathways
WO2008094706A2 (fr) * 2007-02-01 2008-08-07 Cook Incorporated Dispositif de fermeture et procédé de fermeture d'une ouverture corporelle
EP2135155B1 (fr) * 2007-04-11 2013-09-18 Next Holdings, Inc. Système à écran tactile avec procédés de saisie par effleurement et clic
EP2195726A1 (fr) 2007-08-30 2010-06-16 Next Holdings, Inc. Systèmes d'écran tactile extra-plat
KR20100055516A (ko) * 2007-08-30 2010-05-26 넥스트 홀딩스 인코포레이티드 개선된 조광을 가진 광학 터치 스크린
US8405636B2 (en) 2008-01-07 2013-03-26 Next Holdings Limited Optical position sensing system and optical position sensor assembly
US20090207144A1 (en) * 2008-01-07 2009-08-20 Next Holdings Limited Position Sensing System With Edge Positioning Enhancement
US20090213093A1 (en) * 2008-01-07 2009-08-27 Next Holdings Limited Optical position sensor using retroreflection
JP2012504817A (ja) * 2008-10-02 2012-02-23 ネクスト ホールディングス リミティド タッチ検出システムにおいてマルチタッチを解像するステレオ光センサ
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
KR101766619B1 (ko) 2008-12-31 2017-08-08 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
WO2011066343A2 (fr) * 2009-11-24 2011-06-03 Next Holdings Limited Procédés et appareil de commande de mode de reconnaissance de geste
US20110199387A1 (en) * 2009-11-24 2011-08-18 John David Newton Activating Features on an Imaging Device Based on Manipulations
EP2507683A1 (fr) * 2009-12-04 2012-10-10 Next Holdings Limited Procédés et systèmes de détection de position à l'aide d'un volume interactif
US20110234542A1 (en) * 2010-03-26 2011-09-29 Paul Marson Methods and Systems Utilizing Multiple Wavelengths for Position Detection
CN104902930A (zh) 2012-08-21 2015-09-09 阿德利克斯公司 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PT2983667T (pt) 2013-04-12 2019-07-11 Ardelyx Inc Compostos e métodos de ligação ao nhe3 para inibir o transporte de fosfato
SI3173408T1 (sl) 2014-07-25 2019-01-31 Taisho Pharmaceutical Co., Ltd., Spojina fenil tetrahidroizokinolin substituirana s heteroarilom
MA47203A (fr) 2017-01-09 2019-11-13 Ardelyx Inc Inhibiteurs d'antiport à médiation par nhe
CA3049678A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composes utiles pour le traitement de troubles du tractus digestif
EA202090438A1 (ru) 2017-08-04 2020-06-15 Арделикс, Инк. Производные глицерретиновой кислоты для лечения гиперкалиемии
JP2022519714A (ja) 2019-02-07 2022-03-24 アルデリックス， インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131187A (en) * 1964-04-28 Certain z-guantoino-x-aryl-quinazolines
FR2460224A1 (fr) * 1979-06-29 1981-01-23 Renault Regulateur d'allure pour vehicule automobile
FR2685667B1 (fr) * 1991-12-26 1994-07-29 Landerretche Alain Dispositif d'assistance au controle de la puissance de vehicules equipes d'un moteur a combustion interne.
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
DE10043667A1 (de) * 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03055490A1 *

Also Published As

Publication number Publication date
WO2003055490A1 (fr) 2003-07-10
BR0215294A (pt) 2005-02-09
CA2471524A1 (fr) 2003-07-10
MXPA04006193A (es) 2004-12-06
PL369855A1 (en) 2005-05-02
AR037973A1 (es) 2004-12-22
AU2002356762A1 (en) 2003-07-15
DE10163992A1 (de) 2003-07-03
KR20040066856A (ko) 2004-07-27
US20050020612A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
EP1458396A1 (fr) 4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3
EP0667341B1 (fr) 4-Amino-1-pipéridylbenzoyl guanidines comme inhibiteurs Na+/H+ antiporter
WO2001079186A1 (fr) 2-guanidino-4-arylquinazolines utilisees comme inhibiteurs de nhe-3
EP1794128A1 (fr) 4-phenyltetrahydro-isoquinolines substituees, procede permettant de les produire, leur utilisation comme medicament et medicament les contenant
WO2002020496A1 (fr) 2-guanidino-4-aryl-quinazoline
EP1214291A1 (fr) Derives biphenyliques utilises comme inhibiteurs de nhe-3
EP1838315A1 (fr) 4-phenyltetrahydroisochinolines substituees, procede pour les preparer, leur utilisation en tant que medicament et medicament les contenant
EP0670318A2 (fr) Acétamides ayant une activité analgésique et neuroprotectrice
WO2001072742A1 (fr) Composes bisamidino utilises comme inhibiteurs de nhe-3
DE4034785A1 (de) 1-(2-arylethyl)-pyrrolidine
EP1453823A1 (fr) 2-guanidino-4-heterocyclyl-chinazoline
EP0699660B1 (fr) Arylbenzoylguanidines
EP1633741A1 (fr) Derives d'indole en tant qu'inhibiteurs de la recapture de la serotonine
EP1999113B1 (fr) 1-amino-4-phényl-dihydroisoquinoléines substituées, procédé de préparation, utilisation en tant que médicament et médicament les contenant
EP1513834A1 (fr) Thiophenes substitues, procedes de fabrication, utilisation en tant que medicament ou agent diagnostique et medicament contenant ces thiophenes
EP1999112B1 (fr) 2-amino-4-phényl-dihydroquinoléines substituées, procédé de préparation, utilisation en tant que médicament et médicament les contenant
EP1664058B1 (fr) Thienoimidazoles substitues, procede de production, utilisation comme medicament ou produit de diagnostic et medicaments contenant ces composes
EP0008014A1 (fr) Dérivés de la 1-(4-aminopipéridino)-3.4-dihydroisoquinoléine, procédés pour leur préparation, compositions pharmaceutiques les contenant et leur utilisation
DE3907512A1 (de) Neue aryloxy-alkylamine, deren herstellung und diese enthaltende arzneimittel
DE3744149A1 (de) 5-(2,3,4,5-tetrahydro-1h-1-benzazepinyl) -3,6-dihydro-1,3,4-thiadiazin-2-one

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050531